Pharmaron Beijing 康龙化成
19 significant filings since 30 May 2026: 1 on share pledge, 7 on equity incentive and 3 on pledge released, and 5 other kinds. The latest, on 22 Sep 2026: 关于公司实际控制人的一致行动人部分股份解除质押的公告. On 13 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 4.00% to 10.00% from the same period a year earlier.
自 30 May 2026 起有 19 份重大公告：share pledge 1 份、equity incentive 7 份、pledge released 3 份，另有 5 类。最新一份（22 Sep 2026）：关于公司实际控制人的一致行动人部分股份解除质押的公告。13 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 4.00% 至 10.00%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 29 Apr 2025 | 浦银国际证券 | 阳景,胡泽宇 | Neutral 中性 | ▲ | Buy 买入 |
| 6 Apr 2023 | 浦银国际证券 | 丁政宁,胡泽宇 | Buy 买入 | ▼ | Neutral 中性 |
| 17 Mar 2021 | 西南证券 | 杜向阳,马云涛 | Outperform 增持 | ▲ | Buy 买入 |
| 1 Apr 2020 | 万联证券 | 姚文 | Outperform 增持 | ▲ | Buy 买入 |
| 28 Oct 2019 | 民生证券 | 孙建 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 长城国瑞证券 | 胡晨曦,魏钰琪 | Buy 买入 | 26 Aug 2026 | 2 | — |
| 开源证券 | 余汝意 | Buy 买入 | 24 Aug 2026 | 2 | — |
| 招银国际 | Benchen Huang,Jill Wu | Buy 买入 | 24 Aug 2026 | 4 | 56.00 |
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 5 Aug 2026 | 2 | — |
| 西南证券 | 杜向阳 | Unrated | 9 Apr 2026 | 1 | — |
| 浦银国际证券 | 阳景,胡泽宇 | Buy 买入 | 3 Nov 2025 | 1 | 39.60 |
| 信达证券 | 唐爱金,贺鑫 | Unrated | 30 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 5 of 13 reports. 每行为该券商近十二个月的最新研报；13 份中 5 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。